Pax-5 protein expression in bladder cancer: A preliminary study that shows no correlation to grade, stage or clinical outcome

Pathology

Volumn 40, Issue 5, 2008, Pages 465-469

  Denzinger, Stefan ^a   Burger, Maximilian ^a   Hammerschmied, Christine G ^b   Wieland, Wolf F ^a   Hartmann, Arndt ^b   Obermann, Ellen C ^a   Stoehr, Robert ^b,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Bladder cancer; Immunohistochemistry; Pax 5; Tissue microarray

Indexed keywords

MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR PAX5;

ARTICLE; BLADDER CANCER; CANCER GRADING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 46749128247     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802197871     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47: 5-27.
2. Kiemeney LA, Witjes JA, Heijbroek, Verbeek ALM, Debriyne FMJ. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60-4.
3. Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994; 43: 782-6.
4. Vollmer RT, Humprey PA, Swanson PE, et al. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B2, epidermal growth factor receptor, and bcl-2. Cancer 1998; 82: 715-23.
5. Tsujihashi H, Nakanishi A, Matsuda H, et al. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 1993; 145: 846-9.
6. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU International 2000; 85: 48-53.
7. Robson EJD, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 52: 52-62.
8. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 2004; 22: 55-79.
9. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002; 26: 1343-50.
10. Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specifity than CD79a and selective association with t(8;21) acute myelogenous leukaemia. Cancer Res 2004; 64: 7399-404.
11. Babjuk M, Soukup V, Mares J, et al. Association of PAX5 expression with clinical outcome in patients with pTaT1 transitional cell carcinoma of the bladder. Urology 2006; 67: 756-61.
12. Adshead JM, Ogden CW, Penny MA, Stuart ET, Kessling AM. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU International 1999; 83: 1039-44.
13. th ed. New York: Wiley & Sons, 2002.
14. Mostofi FK, Sobin LH, Torloni H. Histological Typing of Urinary Bladder Tumors. Geneva: World Health Organization, 1973.
15. Eble J, Sauter G, Epstein JI, Sesterhenn IA, editors. Classification of Tumours. Pathology and Gentics of the Tumours of the Urinary System and Male Genital Organs. Lyon: World Health Organization, 2004.
16. Smith JA, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162: 1697-01.
17. Klopocki E, Kristiansen G, Wild PJ, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004; 25: 641-9.
18. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumors: a high-throughput tissue microarray analysis. J Clin Pathol 2007; 60: 709-14.
19. Younis RT, Hesse SV, Anand VK. Evaluation of the utility and cost-effectiveness of obtaining histopathologic diagnosis on all routine tonsillectomy specimens. Laryngoscope 2000; 111: 2166-9.
20. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007; 73: 1-14.
21. Robson EJD, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 6: 52-62.
22. Babjuk M, Soukup V, Mares J, et al. The expression of PAX5, p53 immunhistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 2002; 34: 495-501.
23. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003; 22: 7989-997.
24. Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol 2006; 126: 798-804.
25. Gibson SE, Dong HY, Advani AS, His ED. Expression of the B-cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation. Am J Clin Pathol 2006; 126: 916-24.
26. Krueger KE, Srivastava S. Posttranslational protein modifications. Mol Cell Proteomics 2006; 5: 1799-810.
27. Wu F, Mo YY. Ubiquitin-like protein modification in prostate and breast cancer. Front Biosci 2007; 12: 700-11.
28. van Oers JMM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006; 119: 1212-5.
29. Blaveri E, Brewer JL, Roydasqupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11: 7012-22.
30. Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera R. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma 1999; 34: 25-33.
31. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation of transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003; 63: 4620-5.
32. Stoehr R, Wild P, Hartmann A. Lasermicrodissection - an important prerequisite for the molecular-genetic analysis of bladder cancer. Pathol Res Pract 2003; 199: 355-62.
33. Offersen BV, Knapp MM, Marcussen N, Horman MR, Hamilton-Dutoit S, Overgaard J. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicated good prognosis. Br J Cancer 2002; 87: 1422-30.
34. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23: 5746-56.
35. Kastelan Z, Lukac J, Derezic D, et al. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma. Anticancer Res 2003; 23: 5185-9.